SickKids Inflammatory Bowel Disease Center and Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Institute for Medical Science and Biochemistry, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada.
SickKids Inflammatory Bowel Disease Center and Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Institute for Medical Science and Biochemistry, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada.
Cell Mol Gastroenterol Hepatol. 2019;7(3):555-570. doi: 10.1016/j.jcmgh.2018.12.001. Epub 2018 Dec 13.
The increasing incidence of pediatric inflammatory bowel disease, coupled with the efficiency of whole-exome sequencing, has led to the identification of tetratricopeptide repeat domain 7A (TTC7A) as a steward of intestinal health. TTC7A deficiency is an autosomal-recessively inherited disease. In the 5 years since the original description, more than 50 patients with more than 20 distinct disease-causing TTC7A mutations have been identified. Patients show heterogenous intestinal and immunologic disease manifestations, including but not limited to multiple intestinal atresias, very early onset inflammatory bowel disease, loss of intestinal architecture, apoptotic enterocolitis, combined immunodeficiency, and various extraintestinal features related to the skin and/or hair. The focus of this review is to highlight trends in patient phenotypes and to consolidate functional data related to the role of TTC7A in maintaining intestinal homeostasis. TTC7A deficiency is fatal in approximately two thirds of patients, and, as more patients continue to be discovered, elucidating the comprehensive role of TTC7A could show druggable targets that may benefit the growing cohort of individuals suffering from inflammatory bowel disease.
小儿炎症性肠病发病率不断上升,加上外显子组测序的效率提高,导致 tetratricopeptide repeat domain 7A (TTC7A) 被鉴定为肠道健康的管家。TTC7A 缺乏症是一种常染色体隐性遗传疾病。自最初描述以来的 5 年内,已经发现了 50 多名患有 20 多种不同致病 TTC7A 突变的患者。患者表现出异质性的肠道和免疫疾病表现,包括但不限于多发性肠闭锁、极早发炎症性肠病、肠结构丧失、凋亡性结肠炎、联合免疫缺陷以及与皮肤和/或头发相关的各种肠外特征。本综述的重点是强调患者表型的趋势,并整合与 TTC7A 在维持肠道内稳态中的作用相关的功能数据。大约三分之二的 TTC7A 缺乏症患者会致命,随着越来越多的患者被发现,阐明 TTC7A 的全面作用可能会显示出可治疗的靶点,从而使越来越多的炎症性肠病患者受益。